Board of Directors

Samuel D. Riccitelli

Chairman

Mr. Riccitelli has served as our board Chair since June of 2021and has served as a member of the Board of Directors of Orthopediatrics, Inc. (Nasdaq: KIDS) since 2017, a company focused exclusively on the orthopedic implant needs of children. He recently served as Chief Executive Officer of Pathnostics, LLC, a molecular diagnostics company focused on improving antibiotic stewardship, from 2019 to 2020. From 2017 to 2019, Mr. Riccitelli served as Chairman of the Board of Directors of Precipio, Inc. (Nasdaq: PRPO), a diagnostic services company. From 2012 to 2017, Mr. Riccitelli served as President and Chief Executive Officer and a Director of Signal Genetics, Inc., a publicly traded molecular diagnostic company that was ultimately sold to Miragen Therapeutics, Inc. Mr. Riccitelli was also previously the Executive Vice President and Chief Operating Officer of Genoptix, Inc., a publicly traded diagnostic company that was sold to Novartis in 2011. Mr. Riccitelli served in a number of R&D and general management leadership positions for Becton, Dickinson and Company, as a vice president and general manager and as a board member for BD Ventures, LLC., a venture capital fund. Mr. Riccitelli received a B.A. from Washington and Jefferson College and a M.S. Engineering degree from The University of Texas.

Michael W. Nall

President and Chief Executive Officer

Mr. Nall has over 30 years of healthcare leadership experience and has been our President and CEO since 2013. During this time, the company has transitioned from R and D to Commercialization. Mr. Nall has previously served in Commercial and Operational leadership roles in multiple companies including his most recent role as General Manager, North America Sales and Marketing for GE Healthcare’s Clarient division, leading all aspects of commercialization including Sales, Marketing and Reimbursement for Laboratory Services. Prior to Clarient, Mr. Nall served at Impath, Maquet Surgical, Midwest Medical, CVS Specialty Distribution and American Cyanamid.

Mr. Nall also serves on a non-profit board for the Clearity Foundation which is dedicated to providing support for women diagnosed with Ovarian Cancer.

M. Faye Wilson, CPA, MBA

Ms. Wilson is the chair of Biocept’s audit committee. She has been Principal and President of Wilson Boyles & Co., LLC, a business management and strategic planning consulting firm, since 2003. Ms. Wilson also currently serves on the Board of Directors for IQHQ, a real estate investment trust, as well as Sharp Health Care Systems. She has served on the Board of Directors of Biomed Realty Trust, Inc., Farmers Insurance Group of Companies and The Home Depot, Inc. Ms. Wilson was also a senior officer of Home Depot from 1998 through 2002. From 1992 until 1998, Ms. Wilson served in several senior management roles at Bank of America Corporation including Chairman of Security Pacific Financial Services and Executive Vice President of Bank of America.

David F. Hale

Mr. Hale is the Chairman and CEO of Hale BioPharma Ventures LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. Mr. Hale is a serial entrepreneur who has been involved in the founding and/or development of a number of life sciences technology companies and is currently the Chairman of Oncternal Pharmaceuticals and served as Chairman of our board at Biocept until 2020. He was previously President and CEO of CancerVax Corporation, a cancer therapeutic company from October 2000 through May 2006 when CancerVax merged with Micromet, Inc. He became Chairman of Micromet, Inc. until the sale of the company to Amgen Inc. in 2012. After joining Hybritech, Inc., in 1982, he was President & Chief Operating Officer and became CEO in 1986, when Hybritech was acquired by Eli Lilly and Co. From 1987 to 1997 he was Chairman, President and CEO of Gensia, Inc. He was a co-founder and Chairman of Viagene, Inc. from 1987 to 1995. He was President and CEO of Women First HealthCare, Inc. from January 1998 to June 2000. Prior to joining Hybritech in 1982, Mr. Hale was Vice President and General Manager of BBL Microbiology Systems, a division of Becton, Dickinson & Co. and from 1971 to 1980, held various marketing and sales management positions with Ortho Pharmaceutical Corporation, a division of Johnson & Johnson, Inc.

Mr. Hale previously served as Chairman of Santarus, Inc., Somaxon, Inc., SkinMedica, Inc., CRISIMed, Inc. and Agility Clinical, Inc. He also serves as Chairman of a number of privately held companies, including MDR Aesthetics Inc., Recros Medica, Inc., Clarify Medical, Inc., Neurana Pharmaceuticals, Inc. and Adigica Health, Inc., and as a Director of Neurelis, Inc.

Mr. Hale also is a co-founder and serves on the Board of Directors of BIOCOM, is a former member of the board of Biotechnology Industry Organization, or BIO, and the Biotechnology Institute. Mr. Hale also serves as a member of the board of directors of the San Diego Economic Development Corporation, as a board trustee of Rady Children’s Hospital of San Diego, Chairman of the board of Rady Children’s Institute of Pediatric Genomics and a trustee of the Salk Institute. He is a co-founder of the CONNECT Program in Technology and Entrepreneurship. Mr. Hale holds a B.A. in Biology and Chemistry from Jacksonville State University.

Ivor Royston M.D.

Dr. Royston is the chair of Biocept’s science and technology committee. He has served as President, Chief Executive Officer, and Director of Viracta since 2015. From 1990 to 2017, Dr. Royston was a Managing Partner of Forward Ventures, a life science venture capital firm. From 1990 to 2000, Dr. Royston also held the position of Chief Executive Officer of the Sidney Kimmel Cancer Center. Prior to that, Dr. Royston was the Director of Clinical Immunology at University of California, San Diego Cancer Center. Dr. Royston was the co-founder of Hybritech, Inc., which developed the PSA test for prostate cancer; and the co-founder of IDEC Corporation, which developed Rituxan, the first approved monoclonal antibody therapy for lymphoma, and which subsequently merged with Biogen to form Biogen Idec, now Biogen. Dr. Royston received his B.A. and M.D. degrees from Johns Hopkins University and completed post-doctoral training in internal medicine and medical oncology at Stanford University.

Marsha A. Chandler Ph.D.

Dr. Chandler is the chair of Biocept’s nominating and governance committee. She was the Executive Vice President/Chief Operating Officer of the Salk Institute for Biological Studies since 2007 where she managed approximately 1,000 scientific and administrative personnel, and oversaw all institutional fiscal, administrative and fund-raising activities. From 1997 to 2007 she served as Senior Vice Chancellor for Academic Affairs at the University of California, San Diego, where she was the chief academic officer responsible for the policies and decisions relating to all academic programs and faculty appointments and performance.

Bruce E. Gerhardt, CPA

Mr. Gerhardt is the chair of Biocept’s compensation committee. He has been self-employed, practicing as a Certified Public Accountant, since 1986. He is also a tax and business advisor providing tax compliance for small businesses and upper income individuals. Gerhardt earned his Bachelor of Arts Degree from the University of Southern California in 1973 and is a member of the American Institute of Certified Public Accountants.

Linda Rubinstein

Ms. Rubinstein has been a partner at FLG Partners since 2010. She has over 30 years of operational, financial and capital markets experience and has been CFO of numerous public and private companies. While at FLG, Ms. Rubinstein has served as the permanent or interim CFO of Apexigen, ArmaGen, Five Prime, Ingenuity, iPierian, Kezar, PaxVax, Retrotope, Sublimity, True North and Tunitas, among others. Ms. Rubinstein also has held various positions at life science companies and investment banks, including Solexa, a public genetic analysis instrumentation company, ChemoCentryx, a biotechnology company, RDJ Advisors, a financial and strategic consulting firm, and Lehman Brothers. Ms. Rubinstein received her M.A. and B.A. degrees in Economics from the University of California, Los Angeles.

Antonino Morales

Mr. Morales has more than 30 years of broad leadership experience in the US and Latin America. He has served in multiple senior management or consulting roles with various Fortune 100 companies including Citibank, Bank of America, Arthur Andersen, Mazda North America, and McDonald’s. Mr. Morales led the expansion of Citibank’s consumer finance operation into Latin America and most recently served as president and CEO of Apoyo Financiero, Inc. a Community Development Financial Institution (CDFI). Morales has led multiple private equity backed start-up companies. He earned his Bachelor of Science degree in Finance from the University of Southern California and is a licensed CPA.

Partner with Biocept

Contact us to learn how Biocept can support your research and testing.

Contact us for assistance or to learn more at 888.332.7729.